|Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases|
VJ Bardou, G Arpino, RM Elledge, CK Osborne, GM Clark
Journal of clinical oncology 21 (10), 1973-1979, 2003
|Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome|
G Arpino, VJ Bardou, GM Clark, RM Elledge
Breast cancer research 6 (3), 1-8, 2004
|Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance|
G Arpino, H Weiss, AV Lee, R Schiff, S De Placido, CK Osborne, ...
Journal of the National Cancer Institute 97 (17), 1254-1261, 2005
|Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance|
G Arpino, L Wiechmann, CK Osborne, R Schiff
Endocrine reviews 29 (2), 217-233, 2008
|Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy|
X Cui, R Schiff, G Arpino, CK Osborne, AV Lee
Journal of clinical oncology 23 (30), 7721-7735, 2005
|A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer|
M De Laurentiis, G Arpino, E Massarelli, A Ruggiero, C Carlomagno, ...
Clinical cancer research 11 (13), 4741-4748, 2005
|HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study|
G Arpino, SJ Green, DC Allred, D Lew, S Martino, CK Osborne, ...
Clinical cancer research 10 (17), 5670-5676, 2004
|Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome|
G Arpino, GM Clark, S Mohsin, VJ Bardou, RM Elledge
Cancer 94 (8), 2119-2127, 2002
|Premalignant and in situ breast disease: biology and clinical implications|
G Arpino, R Laucirica, RM Elledge
Annals of internal medicine 143 (6), 446-457, 2005
|Treatment of human epidermal growth factor receptor 2–overexpressing breast cancer xenografts with multiagent HER-targeted therapy|
G Arpino, C Gutierrez, H Weiss, M Rimawi, S Massarweh, L Bharwani, ...
Journal of the National Cancer Institute 99 (9), 694-705, 2007
|Treatment of triple negative breast cancer (TNBC): current options and future perspectives|
M De Laurentiis, D Cianniello, R Caputo, B Stanzione, G Arpino, S Cinieri, ...
Cancer treatment reviews 36, S80-S86, 2010
|Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators|
R Schiff, SA Massarweh, J Shou, L Bharwani, G Arpino, M Rimawi, ...
Cancer chemotherapy and pharmacology 56 (1), 10-20, 2005
|Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy|
CK Osborne, R Schiff, G Arpino, AS Lee, VG Hilsenbeck
The Breast 14 (6), 458-465, 2005
|Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up|
L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ...
Breast cancer research and treatment 136 (3), 795-804, 2012
|Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications|
F Montemurro, S Di Cosimo, G Arpino
Annals of Oncology 24 (11), 2715-2724, 2013
|Lobular neoplasia on core‐needle biopsy—Clinical significance|
G Arpino, DC Allred, SK Mohsin, HL Weiss, D Conrow, RM Elledge
Cancer 101 (2), 242-250, 2004
|Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy|
A Giordano, M Giuliano, M De Laurentiis, G Arpino, S Jackson, BC Handy, ...
Annals of oncology 23 (5), 1144-1150, 2012
|Perspective on circulating tumor cell clusters: why it takes a village to metastasize|
M Giuliano, A Shaikh, HC Lo, G Arpino, S De Placido, XH Zhang, ...
Cancer research 78 (4), 845-852, 2018
|Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype|
L Gerratana, D Basile, G Buono, S De Placido, M Giuliano, S Minichillo, ...
Cancer treatment reviews 68, 102-110, 2018
|Gene expression profiling in breast cancer: a clinical perspective|
G Arpino, D Generali, A Sapino, L Del Matro, A Frassoldati, ...
The Breast 22 (2), 109-120, 2013